

ISO 5840-3:2021 (E)

Cardiovascular implants — Cardiac valve prostheses — Part 3: Heart valve substitutes implanted by transcatheter techniques

Contents

| | |
|---------|--|
| | Foreword |
| | Introduction |
| 1 | Scope |
| 2 | Normative references |
| 3 | Terms and definitions |
| 4 | Abbreviations |
| 5 | Fundamental requirements |
| 6 | Device description |
| 6.1 | General |
| 6.2 | Intended use |
| 6.3 | Design inputs |
| 6.3.1 | Operational specifications |
| 6.3.2 | Performance specifications |
| 6.3.2.1 | General |
| 6.3.2.2 | Transcatheter heart valve system |
| 6.3.2.3 | Implantable device |
| 6.3.2.4 | Delivery system |
| 6.3.3 | Implant procedure |
| 6.3.4 | Packaging, labelling and sterilization |
| 6.4 | Design outputs |
| 6.5 | Design transfer (manufacturing verification/validation) |
| 6.6 | Risk management |
| 7 | Design verification and validation |
| 7.1 | General requirements |
| 7.2 | In vitro assessment |
| 7.2.1 | General |
| 7.2.2 | Test conditions, sample selection and reporting requirements |
| 7.2.3 | Material property assessment |
| 7.2.3.1 | General |
| 7.2.3.2 | Biological safety |
| 7.2.3.3 | Material and mechanical property testing |
| 7.2.4 | Hydrodynamic performance assessment |
| 7.2.5 | Structural performance assessment |
| 7.2.5.1 | General |
| 7.2.5.2 | Implant durability assessment |
| 7.2.5.3 | Device structural component fatigue assessment |
| 7.2.5.4 | Component corrosion assessment |
| 7.2.6 | Design- or procedure-specific testing |
| 7.2.6.1 | General |
| 7.2.6.2 | Device migration resistance |
| 7.2.6.3 | Implant foreshortening (length to diameter) |
| 7.2.6.4 | Crush resistance |
| 7.2.6.5 | Recoil |
| 7.2.6.6 | Radial resistive force (RRF) |
| 7.2.6.7 | Chronic outward force |

- 7.2.6.8 Delivery system design evaluation requirements
- 7.2.6.9 Visibility
- 7.2.7 Device MRI compatibility
- 7.2.8 Simulated use
- 7.2.9 Human factors and usability assessment
- 7.2.10 Implant thrombogenic and haemolytic potential assessment
- 7.3 Preclinical in vivo evaluation
 - 7.3.1 General
 - 7.3.2 Overall requirements
 - 7.3.3 Methods
 - 7.3.4 Test report
- 7.4 Clinical investigations
 - 7.4.1 General
 - 7.4.2 Study considerations
 - 7.4.3 Study endpoints
 - 7.4.4 Ethical considerations
 - 7.4.5 Pivotal studies: Distribution of subjects and investigators
 - 7.4.6 Statistical considerations including sample size and duration
 - 7.4.7 Patient selection criteria
 - 7.4.8 Valve thrombosis prevention
 - 7.4.9 Clinical data requirements
 - 7.4.9.1 General
 - 7.4.9.2 Baseline
 - 7.4.9.3 Peri-procedure data
 - 7.4.9.4 Follow-up data
 - 7.4.9.5 Clinical investigation analysis and reporting
 - 7.4.9.6 Post-market clinical follow-up

Annex A (informative) Description of the transcatheter heart valve system

- A.1 General
- A.2 Description of the transcatheter heart valve substitute
- A.3 Description of delivery system
- A.4 Chemical treatments, surface modifications or coatings
- A.5 Component description
- A.6 Implant procedure

Annex B (informative) Transcatheter heart valve substitute hazard analysis example

- B.1 Hazards, foreseeable sequence of events, hazardous situations, and associated harms

Annex C (informative) Guidelines for verification of hydrodynamic performance — Pulsatile flow testing

- C.1 General
- C.2 Pulsatile-flow testing
 - C.2.1 General
 - C.2.2 Measuring equipment accuracy
 - C.2.3 Test apparatus requirements
 - C.2.4 Test fixture parameters — Minimum performance testing (for transcatheter aortic valves only)
 - C.2.5 Test fixture parameters — Minimum performance testing (for transcatheter mitral valves only)
 - C.2.6 Test parameters — Multi-range hydrodynamic characterization testing (all transcatheter valves)
 - C.2.7 Test procedure
 - C.2.8 Test report

Annex D (normative) Requirements for delivery system design and evaluation

- D.1 General
- D.2 Implant interactions with delivery system
- D.3 Loading of the device into/onto the delivery system
- D.4 Ability to access and deploy

Annex E (informative) Examples of design specific testing

- E.1 Stent creep
- E.2 Environmental degradation

- E.3 Static pressure; “burst” test
- E.4 Calcification
- E.5 Particulate generation
- E.6 Effects of device post-dilatation
- E.7 Expansion uniformity
- E.8 Bailout option evaluation
- E.9 Intentional cracking of a pre-existing prosthesis

Annex F (informative) Preclinical in vivo evaluation

- F.1 General
- F.2 Disposition of evaluations
 - F.2.1 General
 - F.2.2 Haemodynamic performance
 - F.2.3 Ease of use
 - F.2.4 Device migration or embolization
 - F.2.5 Interference with or damage to adjacent anatomical structures
 - F.2.6 Haemolysis
 - F.2.7 Thrombo-embolic events
 - F.2.8 Calcification/mineralization
 - F.2.9 Pannus formation/tissue ingrowth
 - F.2.10 Structural valve deterioration and non-structural dysfunction
 - F.2.11 Assessment of valve and non-valve related pathology

Annex G (normative) Adverse event classification during clinical investigation

- G.1 General
- G.2 Evaluation
- G.3 Data collection requirements
- G.4 Adverse events
- G.5 Adverse device effects
- G.6 Device deficiencies
- G.7 Classification of causal relationships
- G.8 Classification of adverse events
 - G.8.1 General
 - G.8.2 Examples of adverse events
- G.9 Comparison to surgical valve replacement
- G.10 Follow up of SAEs
- G.11 Device-related mortality

Annex H (informative) Multimodality imaging of TAVI and TMVI pre, peri and post-implantation assessments — Examples

- H.1 General
- H.2 Multimodality imaging capabilities
- H.3 Echocardiographic (TTE and TEE) data acquisition
- H.4 Computed tomography data acquisition and reconstruction
- H.5 TAVI & TMVR imaging

Page count: 57